Novartis: shares up after broker raises target
(CercleFinance.com) - Novartis is up slightly (+0.
1%) on Friday after UBS raised its target price for the share of the Swiss drugmaker.
The share has risen to 90.7 Swiss francs, after reaching 91.1 Swiss francs when the market first opened, continuing with its rally since the beginning of the year (+22% year-to-date).
Last month the shares reached their highest level in over a decade, at 91.4 Swiss francs.
UBS - which has a "neutral" rating on the stock - this morning raised its target price for the Basel-based company's share to 87 Swiss francs from 85 Swiss francs.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.
1%) on Friday after UBS raised its target price for the share of the Swiss drugmaker.
The share has risen to 90.7 Swiss francs, after reaching 91.1 Swiss francs when the market first opened, continuing with its rally since the beginning of the year (+22% year-to-date).
Last month the shares reached their highest level in over a decade, at 91.4 Swiss francs.
UBS - which has a "neutral" rating on the stock - this morning raised its target price for the Basel-based company's share to 87 Swiss francs from 85 Swiss francs.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.